https://www.pharmaradar360.com/article/4f2a0b5440c9ab52PharmaRadar360en2026-05-01T10:00:00.000Z第18回「日本新薬こども文学賞」 最優秀賞作品決定https://www.pharmaradar360.com/article/48c0b8ebaa18b192PharmaRadar360en2026-05-01T03:00:00.000Z[KOKUSAI]PMDA-ATC Learning videos have been updatedhttps://www.pharmaradar360.com/article/b93d7e1c9b5c5f73PharmaRadar360en2026-05-01T00:00:00.000Z「健康経営優良法人2026（大規模法人部門）」に認定https://www.pharmaradar360.com/article/046453d1bcf1e535PharmaRadar360en2026-05-01T00:00:00.000ZS&P GlobalによるSustainability Yearbook Member 2026に選定https://www.pharmaradar360.com/article/c3f3087f84d3365cPharmaRadar360en2026-05-01T00:00:00.000ZSanten中国、5つの緑内障点眼薬について、中国本土における独占的な流通および販売促進に関する契約を締結https://www.pharmaradar360.com/article/417a4159c085acb1PharmaRadar360en2026-05-01T00:00:00.000Z後天性眼瞼下垂治療剤「アップニーク®ミニ点眼液0.1%」発売のお知らせhttps://www.pharmaradar360.com/article/afd693c4f410a559PharmaRadar360en2026-05-01T00:00:00.000Z役員人事に関するお知らせhttps://www.pharmaradar360.com/article/e13409b12c8763daPharmaRadar360en2026-05-01T00:00:00.000Z＜花粉症に対する意識調査＞ 花粉症で「パフォーマンスに影響あり」は8割以上 「初期療法（早期治療）」を正しく知っている人の半数以上は「毎年実施」 ～眼科医と気象予報士が解説、花粉飛散期前の対策で春をより快適に～https://www.pharmaradar360.com/article/3b4d4384c2e37b0dPharmaRadar360en2026-05-01T00:00:00.000Zアフリベルセプト硝子体内注射用キット40 mg/mL「バイエル」の発売予定についてhttps://www.pharmaradar360.com/article/786539b5bd42a4e2PharmaRadar360en2026-05-01T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/94e05a9904a907acPharmaRadar360en2026-05-01T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/42518b16bc1ac9dfPharmaRadar360en2026-05-01T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/223f99065ffd4ce6PharmaRadar360en2026-05-01T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/8db4a379ce830f97PharmaRadar360en2026-05-01T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/cc55861cbdf838d6PharmaRadar360en2026-05-01T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/5f9e0e646a7477e7PharmaRadar360en2026-05-01T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/4705d512d97859dfPharmaRadar360en2026-05-01T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/929bdc1b8afd407dPharmaRadar360en2026-05-01T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/16484320acb7bfc9PharmaRadar360en2026-05-01T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/6f2c46400af3c779PharmaRadar360en2026-05-01T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/63e5b9986e249c4ePharmaRadar360en2026-05-01T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/b8dbca32ef5dcfb9PharmaRadar360en2026-05-01T00:00:00.000Z6203https://www.pharmaradar360.com/article/34c387ea0e604297PharmaRadar360en2026-05-01T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/73dbeb46af28d967PharmaRadar360en2026-05-01T00:00:00.000Z2026年度「参天製薬 奨学寄付プログラム」の応募を開始いたしましたhttps://www.pharmaradar360.com/article/1ee131ab50d95d3cPharmaRadar360en2026-04-30T16:08:36.000ZField Safety Notices: 20 to 24 April 2026https://www.pharmaradar360.com/article/4e7fd1a3d6f1dcfbPharmaRadar360en2026-04-30T14:56:33.000ZStrengthening AVIM Therapy’s Regulatory Pathway: A Second FDA Breakthrough Device Designationhttps://www.pharmaradar360.com/article/ba59070a1f2e22e3PharmaRadar360en2026-04-30T13:10:39.000ZDecision: Orphan registered medicinal productshttps://www.pharmaradar360.com/article/8a2fed7861d96882PharmaRadar360en2026-04-30T13:01:45.000ZNasal decongestant sprays and drops containing xylometazoline hydrochloride / oxymetazoline hydrochloride: increased risk of rebound congestion, rhinitis medicamentosa, and tachyphylaxis with overusehttps://www.pharmaradar360.com/article/adddeeb7c4a34d8dPharmaRadar360en2026-04-30T13:00:00.000ZAllergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Monthhttps://www.pharmaradar360.com/article/47d2bdeda79ea215PharmaRadar360en2026-04-30T12:37:15.000ZBioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platformhttps://www.pharmaradar360.com/article/a5473bfe55edc115PharmaRadar360en2026-04-30T12:37:04.000ZMedia – RECORDATI: SUMMARY REPORT OF THE VOTES – ORDINARY AND EXTRAORDINARY GENERAL MEETING OF THE SHAREHOLDERS 29.04.2026https://www.pharmaradar360.com/article/02a2f9cdbf3c3ae1PharmaRadar360en2026-04-30T11:33:54.000Z“DIAFORM RX”https://www.pharmaradar360.com/article/e09621dc108a8039PharmaRadar360en2026-04-30T11:30:00.000ZAptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceuticalhttps://www.pharmaradar360.com/article/17f2beca3d6f8d39PharmaRadar360en2026-04-30T11:11:16.000ZGuidance: The Innovative Devices Access Pathway (IDAP)https://www.pharmaradar360.com/article/d59e85130c40e57aPharmaRadar360en2026-04-30T10:59:00.000ZBristol Myers Squibb Reports First Quarter Financial Results for 2026https://www.pharmaradar360.com/article/729dd889872f19d0PharmaRadar360en2026-04-30T10:45:00.000ZLilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicineshttps://www.pharmaradar360.com/article/ddf8746bbee3b801PharmaRadar360en2026-04-30T10:30:00.000ZMerck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestoneshttps://www.pharmaradar360.com/article/2aab7fb7ed9b4597PharmaRadar360en2026-04-30T08:42:11.000ZMEDIA – Press release (on “il Sole 24 Ore”) – 2025 final payment dividendhttps://www.pharmaradar360.com/article/e282f0aedb8bad55PharmaRadar360en2026-04-30T07:39:25.000ZSixth resumed meeting of the open-ended Intergovernmental Working Group (IGWG 6) on the WHO Pandemic Agreement: PABS instrumenthttps://www.pharmaradar360.com/article/6f64aa10fbae4a6cPharmaRadar360en2026-04-30T05:00:00.000ZRoche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026https://www.pharmaradar360.com/article/4d61cea512104ec7PharmaRadar360en2026-04-30T02:00:00.000ZOtsuka Launches "Educational Materials and Resources by Otsuka" for Educators to Support Health Education in Schools Providing Free Digital Health Education Materials on Heat Illness Prevention and Nutrition Educationhttps://www.pharmaradar360.com/article/04de64b9705d4b40PharmaRadar360en2026-04-30T00:00:00.000ZSmall Ways Calories Add Up in Your Diethttps://www.pharmaradar360.com/article/bbf3d66e789823fePharmaRadar360en2026-04-30T00:00:00.000ZCleveland Clinic Pledges $2.5 Million to Feeding Medina County to Strengthen Food Accesshttps://www.pharmaradar360.com/article/587927555cb7bb87PharmaRadar360en2026-04-29T20:54:52.000ZNote to Industry on Requirement for Bioequivalence Studyhttps://www.pharmaradar360.com/article/33fd7b95c06f9037PharmaRadar360en2026-04-29T19:39:03.000ZInterfarma na Imprensa: Interfarma ressalta importância de previsibilidade regulatória após adiamento da Resolução CMED nº 3/2025https://www.pharmaradar360.com/article/e68c4522b72d4809PharmaRadar360en2026-04-29T18:09:37.000ZInterfarma destaca papel do acesso sustentável à inovação na edição especial do Global Forum 2026https://www.pharmaradar360.com/article/c1cd26cd30c8c985PharmaRadar360en2026-04-29T17:25:52.000ZInterfarma e Correio realizam Summit Propriedade Intelectual na Agenda Pública; confira a agendahttps://www.pharmaradar360.com/article/cd533ae407ab757bPharmaRadar360en2026-04-29T15:27:36.000ZDefining Leadership for Oneself is Key to Becoming a Leader, ACRP 2026 Panelists Sayhttps://www.pharmaradar360.com/article/b84287601b677ff1PharmaRadar360en2026-04-29T15:22:08.000ZABPI celebrates a month of major investment commitments into UK life scienceshttps://www.pharmaradar360.com/article/9b31696c7bd8a84aPharmaRadar360en2026-04-29T14:41:48.000ZAttendees Encouraged to “Act with Courage, Driven by Purpose” as ACRP 2026 Closeshttps://www.pharmaradar360.com/article/b6ff9984e239ebe8PharmaRadar360en2026-04-29T14:00:27.000ZLa AEMPS informa del cese de comercialización y la retirada del mercado de Deliplus Men Depil bajo la ducha